ATH alterity therapeutics limited

PBT2 as an Antiobiotic?, page-3

  1. 3,048 Posts.
    lightbulb Created with Sketch. 1126
    Here are the authors and where they work, no ATH people but in any case PBT2 and a new patent was filed over 1 year ago. Thanks pierre !

    Author Information

    1. Nichaela Harbison-Pricea,
    2. Scott A. Fergusona,
    3. Adam Heikala,
    4. George Taiaroaa,
    5. Kiel Hardsa,
    6. Yoshio Nakatania,
    7. David Rennisonb,
    8. Margaret A. Brimbleb,
    9. Ibrahim M. El-Deebc,
    10. Lisa Bohlmannd,
    11. Christopher A. McDevitte,
    12. Mark von Itzsteinc,
    13. Mark J. Walkerd and
    14. Gregory M. Cooka
    1. aDepartment of Microbiology and Immunology, University of Otago, Dunedin, New Zealand
    2. bSchool of Chemical Sciences, University of Auckland, Auckland, New Zealand
    3. cInstitute for Glycomics, Griffith University, Queensland, Australia
    4. dSchool of Chemistry and Molecular Biosciences, Australian Infectious Diseases Research Centre, The University of Queensland, Queensland, Australia
    5. eDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.2¢
Change
-0.003(20.0%)
Mkt cap ! $109.5M
Open High Low Value Volume
1.3¢ 1.4¢ 1.2¢ $565.0K 45.38M

Buyers (Bids)

No. Vol. Price($)
23 9809727 1.2¢
 

Sellers (Offers)

Price($) Vol. No.
1.3¢ 5073699 6
View Market Depth
Last trade - 16.10pm 14/07/2025 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.